The Economic Effects of Autoimmune Disease Research
Over 50 million Americans live with an autoimmune disease like lupus, type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. We estimate the number of people being diagnosed with an autoimmune disease is rising 3-12% each year. The average journey to diagnosis for patients with an autoimmune disease is 4.5 to 5 years. For some, it can take a lifetime.
Currently, there are few effective treatments for the more than 150 chronic conditions classified as autoimmune diseases. Research undertaken and funded by the National Institutes of Health (NIH) has advanced CAR T-cell therapy, precision immunology, and AI-driven diagnostics. This research is opening new frontiers in care and cures are on the line without continued support for the NIH.
How Autoimmune Diseases Affect the Economy
- 90% of U.S. healthcare spending ($4.5 trillion/year) goes toward chronic diseases, including autoimmunity.
- Rising disability rates, insurance costs, and lost productivity strain the workforce and federal programs.
- Projected cost: $1.79 billion in 2025 for 29 diseases, doubling within 15 years without new treatments.
The Power of Research
- Economically, every $1 invested in research returns $2.56 in economic activity.
- Unlike private industry, public research fuels early innovation, laying the foundation for medical advances.
- The NIH fund discoveries and drive breakthrough treatments like CAR-T therapy, now showing potential to cure autoimmune diseases such as multiple sclerosis and demonstrating promise in others.
Supporting the NIH Strengthens the U.S. Economy
- In FY 2023, NIH funding:
- Generated $92.89 billion in economic output.
- Supported over 400,000 jobs nationwide.
- Fueled a $1.55 trillion biotech and pharmaceutical industry that employs millions.
- NIH funding drives U.S. innovation:
- 76 patents per $100 million invested, fueling startups and new technologies.
- $600 million in additional R&D per 76 patents, multiplying economic returns.
- NIH-funded patents deliver 20% more value than other U.S. patents.
Read more
How Can We Curb the Autoimmune Epidemic? New Paper Suggests a Path Forward